Acanthosis nigricans
☆ AI Dermatology — Free Service
Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
Ho tloaelehile ho batho ba batenya.
relevance score : -100.0%
ReferencesAcanthosis nigricans ke ponahatso ea letlalo la boemo bo ka tlase. Hangata e hlaha mamenong a letlalo joalo ka molara, liphakeng, le groin, e shebahala joalo ka maqeba a matšo a botala bo bosootho a nang le mapheo a sa hlakang. Boemo bona hangata bo amahanngoa le lefu la tsoekere (diabetes mellitus) le ho se tšoana le insulin (insulin resistance), empa maemong a sa tloaelehang, bo ka supa mofetše ka hare ho 'mele. E ka boela ea hlaha ka lebaka la mathata a li‑hormone kapa ho noa meriana e itseng e kang li‑steroids (systemic glucocorticoids) le lipilisi tsa thibelo ea bokhachane (oral contraceptives).
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) ke boemo bo tloaelehileng ba letlalo bo amanang le mathata a fapaneng a bophelo bo botle joalo ka insulin resistance, lefu la tsoekere, botenya, malignancy, mathata a lihormone, le karabelo ea meriana. Ho phekola AN ho shebane le ho rarolla mathata a teng a bophelo bo botle. Qalong, lingaka li hlahloba matšoao a insulin resistance, le akarelletsang botenya, hypercholesterolemia, hypertension, le lefu la tsoekere la mofuta oa 2. Hangata lingaka li fana ka topical retinoids e le khetho ea pele ea phekolo, e ka thusang ho teteaneng ha letlalo. Leha ho le joalo, li ka ’na tsa se ke tsa sebetsana le ho fifala ha letlalo ka botlalo. Mekhoa e meng ea kalafo (salicylic acid, podophyllin, urea, calcipotriol) le eona e hloka ho sebelisoa khafetsa.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Mabaka
Hangata e etsahala ho batho ba ka tlase ho lilemo tse 40, e ka ba lefutso la lefu mme e amahanngoa le botenya kapa lefu la endocrinopathies, joalo ka hypothyroidism, acromegaly, polycystic ovary disease, lefu la tsoekere le hananang le insulin (insulin‑resistant diabetes) kapa lefu la Cushing.
○ Kalafo - Lithethefatsi tsa OTC
#40% urea cream